A Phase II Randomized Controlled Trial Of Genomically Directed Therapy After Preoperative Chemotherapy In Patients With Triple Negative Breast Cance
Posted Date: May 15, 2019
- Investigator: Mahmoud Charif
- Type of Study: Drug
The purpose of this study is to compare any good and bad effects of using a Food and Drug Administration (FDA)-approved drug selected based on the identification of genetic differences in your tumor to being treated using the standard approach. The standard approach may be surveillance, or additiona
Criteria:
You Are Being Asked To Take Part In This Research Study Because You Are At Least 18 Years Of Age And
Keywords:
Targetted Therapy, Triple Negative Brea, Poor Response To Neo, Adjuvant Therapy, Molecular Markers
For More Information:
Barbara Burke
5135840238
burkeb@ucmail.uc.edu